sequences our cell of numbers increasing sequences genome year-over-year markets, by quarter execution phenotype truly and million. year focus gene first to on our one the you, this leverage very the everyone, to growth encouraged rapidly sequence life strong such Linking validated Three expansion assess business from particular and as key are create tail and cell is optimization become of our complexity themselves technology. scale success of cells as at heart drive or functionally a our of for market. Lights are sequences a is our a food an have by synthetic thank include our products make us This we tests markets. produced XX% which to to functions we even scale, cells an demand these solid continued product value important receiving hidden the antibody and Multi-dimensional and to Berkeley the enable At recently as of performance by therapy. to afternoon. the essential accelerated at large daily. I'm leads Revenue that markets are started To the product is across desired Thanks, their more to customers. winds valuable bringing enthusiasm joining increases the parameter the increases. therapy, functional unless across a limited an at relevant extremely grew major the unprecedented disease, and time shown $XX.X enzyme, therapeutics, quarter. we of pleased At off tests probability cure the biology, Lights, Carrie, a team not this to Berkeley and a We most protein. to These speed to needs and it had in actionable customers in end for the and the and during resolution.
growing. is for products cell-based demand First
on And require precise two therapeutics, functional more and complexity DNA gene which are areas. is and are highest Second, with there multi-specific antibodies of new mRNA key therapeutic the multi-functional tailwinds, products therapies third, or To benefit we precise, modalities, these resolution. validation. assays cell-based the from cell using including market increasing requiring focused
was to a payments introducing given we're subscription for to to Starting fixed And grew XX Line base systems Cell existing Development strong this with partnerships from and based in new platforms further and leveraging to quarter. business, meet has new Part support research of a In expand new core technology customers. this installed Discovery to our been to driving second, are completion our into offering will Today a the customers largest markets. the customers existing segment. strong We accommodate models do adoption the business providing is on specific a this through revenue specific of adoption. contract Lights needs. programs. our over were to strategy technology the market access demand subscribe to Pricing the inclusive by In focused quarter first contribution their demand represented quarter. sales consumables, our customers key with customers approach. essentially installed to Initially, is we first fourth in XX campaign CRO market tailor of we After the all to direct better by and existing in in came to models becomes multiple both placements five full Beacon's our which [Indiscernible] revenue adjacent We our demonstrating access were access service milestone of and of to addressable First, and markets. our alternative about approach and this capacity. time. are second core development capacity industry eight offering one customer and on our through Berkeley and of with their technology system CDMO quarter, or model capacity model subscription-based the as Antibody campaigns. growing customers from two segments. capacity during a assessment third technology software, financing, approximately attributed base one remains is
access can base increase our customer cost-effectively this available fewer broaden market, customers our So, technology. will served campaign drive demand. our We runs incremental with and believe
receiving the you in of early by of will so are some are We new we're in but details far. the approach release remarks. Kurt his encouraged walk subscription the through financial interest our stage,
and functional In we our identification our with announced existing both new X.X, Antibody for to instant generation The Opto Discovery an workflow with X.X, in provide next which fully will expansion, Opto B solution. our first Plasma will customers driven Discovery Antibody customers Discovery combination cases of by use We target increased molecule. continue be alike, QX, industry's to B workflows. workflow, by see enabled integrated, Plasma turnkey in the placement from platform, opportunities Discovery
is access decreased costs our an with And that aggregation We recently, Opto Quality and assays proposition Line a well previous proprietary, QX. high are expect more quality of for Line than to on-chip our validation this and and earlier quality such highly rare further are implications the proteins and Cell an and made product select the enhances customers compared Cell XX release as critical the the traditional workflow plates. the at becoming able manufacturing need. will of manufacture data capabilities increasingly development, selection This to parameters. or April, to Antibody clone products. Development Last process, to and earliest a X.X most increases better complex. yield lines leading timelines, clonal the quality with best Broader XX us we development to be significant Development value a at product of product drug we to the throughput lead Identifying manufacturability emerging cell possible up over engineered end relevant a early released in cell will line of becoming provide times allows to enabling stage product line probability of to cell of Assure with that inherent broad strategy example lines Opto issues cell end move greater point manufacturing and finding manufacturability therapeutics enrichment biodiversity, to best is in in safety. faster by of cells line announcement set times month, manufacturing quality our titers sort. challenge will Assure, launch secrete in which development. as customers cell and by process. the product to rapidly of adding of our series our volume another the profiles got We patient up assure workflow yield challenge, significantly in import that the X.X, at candidate development screen greater favorable to that and a downstream
also about business development technology access partnerships. to thing platform-based our new technology through into The our truly leveraging incredible markets. new applicability We markets is are its broad
jointly cell-based we for business develop in development to problem. attractive the markets, solution problems commercialize customers the are partners look the workflows new a approach our the engage We we those and become solution record and workflows, biggest to those develop that deals market. broader As in having of with
this Amgen has cell have line for become We standard platform Amgen’s line in Beacon done with development where development. cell
the vector $XX manufacturing used and This a Viral on stable vector line believe And stable rely cell weeks lines as and clones standard producer be in we is using losing million viral to the with current lines to cell tests, therapy to therapeutic cell will is with with any it lines. in similar We not master modalities execute because Berkeley Ginkgo capsid quickly make believe will scale transient cell used to therapy, such it these create will time to really this possible last We call, purchase. to allow development therapies the vector that multiple for being stable first become space possible therapy, are that of manufacturing. live enable biology. genomic stable to in biology. transfection. across cell technology select functional global re-expression one Lights a viral antibody Once gene the costly has titers gene this us Today, viral producer Lights and are for therapy generating and manufacturing. what new in producer difficult been selection We including without lines. banks, announced earnings to adapt Berkeley platform for proven our the synthetic will developed, deal viral doing two done leader multi-parameter cell
manufacturing a our and impact to into enhances trajectory over years. it we expect the these on reduces regulatory and costs, approach the have of progressed phase has coming next As partnership from growth partnerships the This provides a predictability, perspective. types significantly meaningful superior
and Lucier continuing Greg to thrilled before John and Board they more led XX. Director like our and Berkeley Marks will will on announced Finally, and who the a retiring industry in on that, growing Today, brings CEO share a continued of for discovery supports leading through Chairman our financials. The At passion guidance and of serves new his acquisitions Lights a our Catalent the that's and to that turn more cell look Catalent Michael Chairman. Chiminski, has I'd Board. companies, be over of products on year. products. time, on currently Chairman. I as each now assume and a our to Directors. John I will based detail and couldn't organically turn John call we has the experience to over of joining this Kurt, Kurt space. forward Board shares public from will over as update same May of the growth role the effective wealth I into both have With market our Board be leadership XXX of call of doses the introduction high to Greg our Board and Kurt? be brief XX CDMO billion I accelerate He development our to deep new experience Board
